Sarepta Therapeutics (SRPT-Q) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr03/2026	Next Qtr06/2026	Fiscal Yr12/2026	Fiscal Yr12/2027
Average Estimate	0.26	0.71	2.79	1.34
Number of Estimates	5	5	7	6
High Estimate	1.84	2.31	4.66	3.28
Low Estimate	-0.71	-0.14	1.42	-0.21
Prior Year	-3.84	1.70	-6.29	2.79
Growth Rate Est. (year over year)	+106.77%	-58.24%	+144.36%	-51.97%

Earnings History - Surprises*

	Qtr Ending12/2025	Qtr Ending09/2025	Qtr Ending06/2025	Qtr Ending03/2025
Reported	$-3.87	$-0.28	$1.70	$-3.84
Estimate	$-1.03	$-0.37	$0.78	$-0.87
Difference	-2.84	+0.09	+0.92	-2.97
Surprise	-275.73%	+24.32%	+117.95%	-341.38%

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

3.19

3 Mths Ago27

3.19

2 Mths Ago27

3.19

1 Mth Ago27

3.19

Current27

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	27	27	27	27
	7	7	7	7
Holds	15	15	15	15
	1 4	1 4	1 4	1 4

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

The time may be right to focus on neglected stocks

Robert Tattersall

Bullish on NextEra Energy Inc.

number cruncher

Ten transportation stocks to watch as oil prices rise

The most oversold and overbought stocks on the TSX

Monday’s analyst upgrades and downgrades

Insider Report: Chair sells $5-million from this stock yielding 5.8% that’s doubled in under a year

Canaccord reworks U.S. leadership in wake of regulatory settlement

Bullish on FirstEnergy Corp.